Saving Seniors Money on Prescriptions Act This bill establishes reporting requirements for pharmacy benefit managers (PBMs) under the Medicare prescription drug benefit and Medicare Advantage, particularly relating to the prices of prescription drugs. Specifically, PBMs must (1) disclose certain information underlying cost performance measurements (e.g., exclusions and terms), and (2) report to prescription drug plan (PDP) sponsors (and to the Centers for Medicare & Medicaid Services upon request) an itemized list of prescription drugs that were dispensed during the previous year and related data about costs, claims, affiliated pharmacies, and other specified information. PDP sponsors may audit PBMs to ensure compliance with this bill's requirements and must annually certify their compliance; PBMs are responsible for any associated civil penalties for violations. In addition, the Government Accountability Office must study federal and state reporting requirements for health plans and PBMs with respect to prescription drug price transparency and recommend ways to streamline these requirements.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Bill introduced
Lobbying filed by PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
Lobbying filed by AMERICA'S HEALTH INSURANCE PLANS INC (AHIP)
Lobbying filed by NOVARTIS
Lobbying filed by PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
| Registrant | Client | Amount | Filed | Period | Issues |
|---|---|---|---|---|---|
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | $12.9M | Apr 21, 2025 | 2025Q1 | BUDCPTHCR |
| AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP) | AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | $4.8M | Apr 21, 2025 | 2025Q1 | HCRMMMINS |
The lobbying table lists Senate LDA quarterly reports (LD-2) that cite this bill by number and cover a quarter of the 119th Congress. An LD-2 names a bill as “H.R. 1234” with no Congress, so a report on another Congress, which can only concern a different bill with the same number, is left out, even when it was filed after this Congress began. The amount is what the registrant reported for the whole filing, across every issue on it, not spending on this bill. Official actions and the bill summary come from Congress.gov, and votes from the roll-call record. This page no longer pairs the bill with members' stock trades: matching lobbying clients to traded companies by name, and trades to a bill by date, is not something the records establish.
Lobbying filed by AMERICA'S HEALTH INSURANCE PLANS INC (AHIP)
| NOVARTIS |
| NOVARTIS |
| $4.2M |
| Apr 21, 2025 |
| 2025Q1 |
BUDCPTHCR |
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | $4.1M | Apr 21, 2025 | 2025Q1 | MMMHCRPHA |
| AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP) | AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | $4.0M | Jul 21, 2025 | 2025Q2 | HCRMMMINS |
| NOVARTIS | NOVARTIS | $880.0K | Jul 21, 2025 | 2025Q2 | BUDCPTHCR |
| GSK (FKA GLAXOSMITHKLINE INC.) | GSK (FKA GLAXOSMITHKLINE INC.) | $800.0K | Apr 21, 2025 | 2025Q1 | BUDCPTHCR |